Telix Pharmaceuticals Ltd ADR (TLX): Next-Year EPS Estimate 28.73%
As of 2026-08-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 28.73%. Featured in our EPS revision report on 2026-04-13.
On 2026-08-20, analyst consensus for TLX's next-year EPS growth shifted from 154.21% to 28.73% — a negative change of 125.48 percentage points. Current-year growth is projected at 373.04%.
What's Driving This
Telix's rise is not supported by an EPS upgrade: on 2026-08-20 analysts cut the next-year EPS growth estimate from 154.21% to 28.73%, a 125.48 pp reduction. The move instead coincides with the Regeneron strategic
Generated 2026-11-04 from news as of 2026-08-20
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 28.73%
- EPS growth this year
- 373.04%
- EPS next quarter (est)
- $0.00
- Last price
- $12.36
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-20 | 28.73% | 373.04% | $0.00 | $12.36 |
| 2026-08-19 | 154.21% | 274.06% | N/A | $12.12 |
| 2026-08-18 | 154.21% | 274.06% | N/A | $11.88 |
| 2026-08-17 | 154.21% | 274.06% | N/A | $11.73 |
| 2026-08-16 | 154.21% | 274.06% | N/A | $11.82 |
| 2026-08-14 | 154.21% | 274.06% | N/A | $11.82 |
| 2026-08-13 | 154.21% | 274.06% | N/A | $12.33 |
| 2026-08-12 | 154.21% | 274.06% | N/A | $11.97 |
| 2026-08-11 | 154.21% | 274.06% | N/A | $12.00 |
| 2026-08-10 | 154.21% | 274.06% | N/A | $11.79 |
| 2026-08-09 | 154.21% | 274.06% | N/A | $11.52 |
| 2026-08-07 | 154.21% | 274.06% | N/A | $11.52 |
| 2026-08-06 | 154.21% | 274.06% | N/A | $10.64 |
| 2026-08-05 | 154.21% | 274.06% | N/A | $10.42 |
| 2026-08-04 | 154.21% | 274.06% | N/A | $10.29 |
| 2026-08-03 | 154.21% | 274.06% | N/A | $10.02 |
| 2026-08-02 | 154.21% | 274.06% | N/A | $9.89 |
| 2026-07-31 | 154.21% | 274.06% | N/A | $9.89 |
| 2026-07-30 | 154.21% | 274.06% | N/A | $10.06 |
| 2026-07-29 | 154.21% | 274.06% | N/A | $10.10 |
| 2026-07-28 | 154.21% | 274.06% | N/A | $10.19 |
| 2026-07-27 | 119.25% | 301.82% | N/A | $9.98 |
| 2026-07-26 | 119.25% | 301.82% | N/A | $10.22 |
| 2026-07-24 | 119.25% | 301.82% | N/A | $10.22 |
| 2026-07-23 | 117.86% | 304.18% | N/A | $10.51 |
| 2026-07-22 | 117.86% | 304.18% | N/A | $10.32 |
| 2026-07-21 | 121.88% | 312.31% | N/A | $10.92 |
| 2026-07-20 | 136.73% | 313.86% | N/A | $10.51 |
| 2026-07-19 | 173.98% | 268.67% | N/A | $10.46 |
| 2026-07-17 | 173.98% | 268.67% | N/A | $10.46 |
Reports Featuring TLX
Recent News
- Telix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswire
- FDA Accepts NDA for TLX101-Px (Pixclara)GlobeNewswire
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-08-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 28.73%, based on analyst consensus.
When was the latest EPS estimate revision for TLX?▾
The most recent revision occurred on 2026-08-20, when analysts adjusted the next-year EPS growth estimate from 154.21% to 28.73%.
What sector and industry does Telix Pharmaceuticals Ltd ADR belong to?▾
Telix Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TLX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.